Showing results (111-120 of 444) with videos related to
Sort By:
Pageof 45
Expert Opinion on Drug Safety|March 7, 2014
Prospects for MEK inhibitors for treating cancerJuan Martin-Liberal, Laura Lagares-Tena, James LarkinJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2024
Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still OutAndreas Michael Schmitt, James Larkin, Sapna P PatelNeuro-Oncology Advances|July 28, 2025
Impact of stereotactic radiosurgery timing relative to immune checkpoint blockade administration on brain metastasis disease and radionecrosis outcomesAnika Mittal, Aviva Green, Xavier Fitzgerald, et al.Stem Cell Research|November 16, 2024
Generation of TWO iPSC lines (CRICKi009-A; CRICKi010-A) from patients with type 1 von Hippel-Lindau (VHL) and histopathologically confirmed renal cell carcinoma (RCC)Liani G Devito, Eugénie S Lim, Samuel M O'Toole, et al.Expert Opinion on Pharmacotherapy|May 23, 2015
BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanomaJuliet Richman, Juan Martin-Liberal, Stefan Diem, et al.Expert Opinion on Pharmacotherapy|April 27, 2019
Current and emerging systemic therapies for cutaneous metastatic melanomaRobert Mason, Lewis Au, Alvaro Ingles Garces, et al.International Journal of Cancer|July 10, 2026
10-Years of First-Line Ipilimumab and Nivolumab in Advanced Melanoma: A Single Centre ExperienceAnadil Javaid, Tobias Peres, Andreas Michael Schmitt, et al.Expert Review of Anticancer Therapy|April 16, 2020
Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacyIsla Leslie, Laura Amanda Boos, James Larkin, et al.The International Journal on Drug Policy|April 4, 2025
Prioritising research on marketing and consumption of No and Low (NoLo) alcoholic beverages in IrelandEmeka W Dumbili, Paula Leonard, James Larkin, et al.Lancet (London, England)|December 7, 2020
Enhancing anti-tumour efficacy with immunotherapy combinationsFunda Meric-Bernstam, James Larkin, Josep Tabernero, et al.Pageof 45